Abstract:Local control rates after SCRT (50 Gy) are very poor in advanced esophageal cancer. Most local failures (LF) occur in the GTV. HFRT allows for delivering a higher total dose without increasing late toxicity. We hypothesized that the use of HFRT boost to the GTV after SCRT using modern image-guided intensity-modulated radiation therapy (IG-IMRT) could potentially intensify local therapy and subsequently improve outcomes. The primary objective of this phase I trial was to define the maximum tolerated dose (MTD) of the HFRT boost with concurrent weekly C/P following SCRT. Patients (pts) who were inoperable or medically unresectable and metastatic with life expectancy ≥ 4 months were eligible. The lower thoracic esophageal cancer involving the stomach was ineligible. Pts were treated with weekly P at 45 mg/m2 and C area under the curve 1.5 with concurrent 50 Gy of IG-IMRT given in 25 fractions for 5 weeks, immediately followed by an image-guided intensity-modulated HFRT boost to the GTV concurrent with the same chemotherapy regimen. The boost doses were escalated ranging from 7.2 to 43.2 Gy in increments of 7.2 Gy delivered in 6 twice daily fractions of 1.2 Gy using a modified Fibonacci design. A minimum of 6 weeks follow-up was required after completion of radiation treatment before proceeding to the next dose. Dose limiting toxicity (DLT) was defined as grade ≥ 4 esophagitis or any other grade ≥ 3 non-hematological toxicity (except nausea and vomiting) or grade ≥ 4 hematological toxicity lasting more than 7 days, which are possibly, probably or definitely associated with protocol treatment occurring during and after completion of the HFRT boost treatment. The MTD was defined as the highest radiation dose at which ≤ 1 pts experienced DLT. Once the MTD was determined, this cohort was expanded to further define the safety profile. Adjuvant chemotherapy was optional. Thirty-four pts were enrolled and 31 were assessable (median age, 62 years; 73% male; 97% T3-4 disease, 65% N1-2 disease; 9% M1 disease; 97% squamous cell carcinoma; 90% PS 0-1).SCRT was well tolerated. The incidence of DLT was 0/3, 0/3, 0/3, 1/6 (grade 4 esophagitis), 0/3, 2/3 (grade 5 esophageal fistula and grade 3 pneumotitis each) at 7.2, 14.4, 21.6, 28.8, 36, and 43.2 Gy, respectively, thus defining the MTD at 36 Gy. In the expansion cohort of 10 pts at the MTD, no DLTs were encountered. The most common acute grade 3 or greater toxicities throughout the entire study period were esophagitis (26%) and neutropenia (19%). Late toxicity included grade 2 esophageal stricture (n = 4). The overall response rate was 84% (95% CI, 42% to 93%; 100% at a dose of ≥ the MTD). With a median follow up of 5 months (range 1 to 12 months), no LF was observed, and distant failure occurred in 3 pts. The MTD of a HFRT boost was determined to be 36 Gy using IG-IMRT with concurrent P and C following 50 Gy of SCRT, resulting in the total combined tumor dose of 86 Gy. Preliminary efficacy data are encouraging. A Phase II study to further evaluate this regimen is underway.

Radical chemoradiotherapy for superficial esophageal cancer complicated with liver cirrhosis

Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.

Phase I Study of Dose-Escalated Intensity-Modulated Hyperfractionated Radiation Therapy (HFRT) Boost with Concurrent Paclitaxel (P) and Carboplatin (C) to Gross Tumor Volume (GTV) Following Standard-Dose Chemoradiotherapy (SCRT) for Advanced Esophageal Ca

461. SURGICAL TREATMENT OF STAGE IV ESOPHAGEAL CANCER AFTER CCRT IMPROVES SURVIVAL

Clinical Evaluation of Transarterial Infusion Chemotherapy for Advanced Esophageal Cancer

Dose escalation in radical radio(chemo)therapy for cervical and upper thoracic esophageal cancer with 3DCRT/IMRT (ChC&UES): a multicenter retrospective study

Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?

Survival rates and safety associated with chemoradiotherapy followed by surgery and chemoradiotherapy alone for patients with T4 esophageal cancer: a systematic review and meta-analysis

Clinical study of postoperative chemoradiotherapy of thoracic esophageal squamous cell carcinoma with positive lymph nodes

Long-Term Clinical Outcomes and Safety Analysis of Superficial Esophageal Cancer Patients Treated with Definitive or Adjuvant Radiotherapy

Safety and Efficacy of Radiotherapy in Combination with Immunochemotherapy for Advanced Esophageal Cancer: A Retrospective Analysis.

High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma

Upper Gastrointestinal Cancer and Liver Cirrhosis

[Phase II Clinical Trial of Concurrent Chemoradiotherapy (cisplatin Plus 5-Fluorouracil) for Esophageal Cancer].

[Value of Postoperative Radiochemotherapy for Thoracic Esophageal Squamous Cell Carcinoma with Lymph Node Metastasis].

Clinical outcomes of esophageal squamous cell carcinoma in patients with cirrhosis

Concurrent Three Dimensional Conformal Radiotherapy and Chemotherapy with DF Regime in the Treatment for 33 Cases with Advanced Esophageal Carcinoma

Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy

Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial

Meta-analysis of Late Course Accelerated Hyperfractionated Radiotherapy Combined with FP Chemotherapy for Esophageal Carcinoma

[A Multi-Centered Randomized Controlled Study of Neo-Adjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of Esophagus: an Interim Analysis].